Renal revascularization in resistant hypertension.
Renal artery stenosis
Renal artery stenting
Resistant hypertension
Journal
Progress in cardiovascular diseases
ISSN: 1873-1740
Titre abrégé: Prog Cardiovasc Dis
Pays: United States
ID NLM: 0376442
Informations de publication
Date de publication:
Historique:
received:
03
12
2019
accepted:
03
12
2019
pubmed:
11
12
2019
medline:
12
5
2020
entrez:
11
12
2019
Statut:
ppublish
Résumé
Renal artery stenosis (RAS) is a common cause of secondary hypertension (HTN) and may lead to resistant (refractory) HTN despite guideline directed medical therapy. Although randomized controlled trials comparing medical therapy to medical therapy and renal artery stenting have shown no benefit with renal artery stenting, according to comparative effectiveness reviews by the Agency for Healthcare Research and Quality, the trials did not enroll patients with the most severe RAS who would be more likely to benefit from renal stenting. Because of limitations of conventional angiography, it is important to assess the hemodynamic severity of moderate (50%-70%) RAS lesions with a hemodynamic measurement. We review techniques to optimize patient selection, to minimize procedural complications, and to facilitate durable patency of renal stenting. We also review the current ACC/AHA Guidelines and SCAI Appropriate Use Criteria as they relate to renal stenting.
Identifiants
pubmed: 31821813
pii: S0033-0620(19)30161-6
doi: 10.1016/j.pcad.2019.12.001
pii:
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
58-63Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.